ArticleTherapeutic advances in medical oncology2026
Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While trifluridine/tipiracil (FTD/TPI) is approved for refractory metastatic colorectal cancer (mCRC), its clinical benefit may vary based on molecular and clinical characteristics. Objectives: To identify clinical and molecular factors associated with overall survival (OS) in patients with refractory mCRC treated with FTD/TPI. Design: Retrospective, multicenter study. Methods: A retrospective multicenter cohort study of 591 mCRC patients treated with FTD/TPI was conducted. Cox regression was used to identify independent prognostic factors for overall survival (OS). Results: Median OS was 7.8 months in the overall cohort. Patients with deficient mismatch repair (dMMR) had significantly longer OS than those with proficient MMR ( Conclusion: In this retrospective multicenter cohort, MMR status, BMI, and neutrophil-to-lymphocyte ratio (NLR) were identified as factors independently associated with OS among patients with refractory mCRC treated with FTD/TPI. These findings support the integration of molecular and clinical factors for prognostic stratification in later-line treatment settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.